Home / Business and Economy / Roivant's LISRAYA Launch Exceeds Expectations
Roivant's LISRAYA Launch Exceeds Expectations
10 Nov
Summary
- LISRAYA generated $31.0 million in its first 5 weeks post-launch.
- IMVT-1402 showed a 92.5% ACR20 response rate in rheumatoid arthritis.
- Roivant maintains $4.2 billion in cash, boosted by a Moderna settlement.
Roivant Sciences has achieved significant milestones, highlighted by the successful commercial launch of LISRAYA. In its initial five weeks, the drug generated $31.0 million in net product revenue, indicating strong market reception.
The company also reported impressive clinical data for IMVT-1402 in rheumatoid arthritis, with a 92.5% ACR20 response rate at week 28 in the 600 mg dose group. Further positive developments include strong outcomes for brepocitinib in noninfectious uveitis and mosliciguat in pulmonary hypertension associated with interstitial lung disease.
Financially, Roivant maintains a robust position with $4.2 billion in cash and marketable securities as of September 30, 2026, significantly supported by an initial payment from a patent settlement with Moderna. The company is advancing its strategic plans, including filing a supplemental New Drug Application for brepocitinib.
Despite challenges such as managing payer access policies for LISRAYA, Roivant remains optimistic about its pipeline's potential. Discussions with the FDA regarding IMVT-1402 are ongoing, aiming to define the registrational path forward for this promising therapy.
